Nanobiotechnology applications of reconstituted high density lipoprotein

Journal of Nanobiotechnology

Volumn 8, Issue , 2010, Pages

  Ryan, Robert O ^a,b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIPATHIC; AMPHIPHILICS; APOLIPOPROTEINS; BASIC BUILDING BLOCK; BIOLOGICAL ACTIVITIES; CHOLESTEROL TRANSPORT; CONTRAST AGENT; HIGH DENSITY LIPOPROTEIN; HIGH-DENSITY LIPOPROTEINS; IN-VITRO; INTEGRAL MEMBRANE PROTEINS; NANODISKS; PHOSPHOLIPID BILAYER;

BIOLOGICAL MEMBRANES; GADOLINIUM; PHOSPHOLIPIDS; PROTEINS; RESONANCE;

MAGNETIC RESONANCE IMAGING;

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTHRAX TOXIN; ANTIBIOTIC AGENT; BACTERIORHODOPSIN; BETA 2 ADRENERGIC RECEPTOR; CHELATING AGENT; CONTRAST MEDIUM; CURCUMIN; CYTOCHROME P450; DIAGNOSTIC AGENT; DIETHYLENETRIAMINEPENTAACETATE DIMYRISTOYLPHOSPHATIDYLETHANOLAMINE GADOLINIUM; GADOLINIUM; HEMAGGLUTININ; HIGH DENSITY LIPOPROTEIN; HYDROGENASE; INFLUENZA VACCINE; ISOPRENOID; MEMBRANE PROTEIN; POLYPHENOL; PROTEIN SECA; PROTEIN SECYEG; RECOMBINANT HEMAGGLUTININ; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; RETINOIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1;

ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BILAYER MEMBRANE; CANDIDIASIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA A (H1N1); LEISHMANIASIS; MANTLE CELL LYMPHOMA; MOLECULE; NANOBIOTECHNOLOGY; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHARMACODYNAMICS; PROMYELOCYTIC LEUKEMIA; PROTEIN CONFORMATION; RETINOIC ACID SYNDROME; X RAY CRYSTALLOGRAPHY;

EID: 78649512581     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-8-28     Document Type: Article

References (61)

1. Fielding CJ. High Density Lipoproteins. 2007, Weinheim: Wiley-VCH.
2. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010, 21:229-238. 10.1097/MOL.0b013e328338472d, 20480549.
3. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010, 55:1283-1299. 10.1016/j.jacc.2010.01.008, 20338488.
4. Dudley-Brown S. A shot of good cholesterol: synthetic HDL, a new intervention for atherosclerosis. J Cardiovasc Nurs 2004, 19:421-424.
5. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300. 10.1001/jama.290.17.2292, 14600188.
6. Jonas A. Reconstitution of high-density lipoproteins. Methods Enzymol 1986, 128:553-582. full_text, 3724523.
7. Weers PM, Narayanaswami V, Ryan RO. Modulation of the lipid binding properties of the N-terminal domain of human apolipoprotein E3. Eur J Biochem 2001, 268:3728-3735. 10.1046/j.1432-1327.2001.02282.x, 11432739.
8. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001, 42:1096-1104.
9. Nath A, Atkins WM, Sligar SG. Applications of phospholipid bilayer nanodiscs in the study of membranes and membrane proteins. Biochemistry 2007, 46:2059-2069. 10.1021/bi602371n, 17263563.
10. Borch J, Hamann T. The nanodisc: a novel tool for membrane protein studies. Biol Chem 2009, 390:805-814. 10.1515/BC.2009.091, 19453280.
11. Ritchie TK, Grinkova YV, Bayburt TH, Denisov IG, Zolnerciks JK, Atkins WM, Sligar SG. Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. Methods Enzymol 2009, 464:211-231. full_text, 19903557.
12. Bayburt TH, Sligar SG. Membrane protein assembly into Nanodiscs. FEBS Lett 2010, 584:1721-1727. 10.1016/j.febslet.2009.10.024, 19836392.
13. Henderson R, Unwin PN. Three-dimensional model of purple membrane obtained by electron microscopy. Nature 1975, 257:28-32. 10.1038/257028a0, 1161000.
14. Bayburt TH, Grinkova YV, Sligar SG. Assembly of single bacteriorhodopsin trimers in bilayer nanodiscs. Arch Biochem Biophys 2006, 450:215-222. 10.1016/j.abb.2006.03.013, 16620766.
15. Blanchette CD, Cappuccio JA, Kuhn EA, Segelke BW, Benner WH, Chromy BA, Coleman MA, Bench G, Hoeprich PD, Sulchek TA. Atomic force microscopy differentiates discrete size distributions between membrane protein containing and empty nanolipoprotein particles. Biochim Biophys Acta 2008, 1788:724-731.
16. Baas BJ, Denisov IG, Sligar SG. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. Arch Biochem Biophys 2004, 430:218-228. 10.1016/j.abb.2004.07.003, 15369821.
17. Das A, Sligar SG. Modulation of the cytochrome P450 reductase redox potential by the phospholipid bilayer. Biochemistry 2009, 48:12104-12112. 10.1021/bi9011435, 19908820.
18. Leitz AJ, Bayburt TH, Barnakov AN, Springer BA, Sligar SG. Functional reconstitution of Beta2-adrenergic receptors utilizing self-assembling Nanodisc technology. Biotechniques 2006, 40:601-602. 10.2144/000112169, 16708760.
19. Baker SE, Hopkins RC, Blanchette CD, Walsworth VL, Sumbad R, Fischer NO, Kuhn EA, Coleman M, Chromy BA, Létant SE, Hoeprich PD, Adams MW, Henderson PT. Hydrogen production by a hyperthermophilic membrane-bound hydrogenase in water-soluble nanolipoprotein particles. J Am Chem Soc 2009, 131:7508-7509. 10.1021/ja809251f, 19449869.
20. Driessen AJ, Nouwen N. Protein translocation across the bacterial cytoplasmic membrane. Annu Rev Biochem 2008, 77:643-67. 10.1146/annurev.biochem.77.061606.160747, 18078384.
21. Alami M, Dalal K, Lelj-Garolla B, Sligar SG, Duong F. Nanodiscs unravel the interaction between the SecYEG channel and its cytosolic partner SecA. EMBO J 2007, 26:1995-2004. 10.1038/sj.emboj.7601661, 1852787, 17396152.
22. Katayama H, Wang J, Tama F, Chollet L, Gogol EP, Collier RJ, Fisher MT. Three-dimensional structure of the anthrax toxin pore inserted into lipid nanodiscs and lipid vesicles. Proc Natl Acad Sci USA 2010, 107:3453-3457. 10.1073/pnas.1000100107, 2840458, 20142512.
23. Raschle T, Hiller S, Yu TY, Rice AJ, Walz T, Wagner G. Structural and functional characterization of the integral membrane protein VDAC-1 in lipid bilayer nanodiscs. J Am Chem Soc 2009, 131:17777-17779. 10.1021/ja907918r, 19916553.
24. Bhattacharya P, Grimme S, Ganesh B, Gopisetty A, Sheng JR, Martinez O, Jayarama S, Artinger M, Meriggioli M, Prabhakar BS. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol 2010, 84:361-371. 10.1128/JVI.01355-09, 2798435, 19828606.
25. Ryan RO. Nanodisks: hydrophobic drug delivery vehicle. Expert Opin Drug Deliv 2008, 5:343-351. 10.1517/17425247.5.3.343, 18318655.
26. Iovannisci DM, Beckstead JA, Ryan RO. Targeting nanodisks via an apolipoprotein - single chain variable antibody chimera. Biochem Biophys Res Commun 2009, 379:466-469. 10.1016/j.bbrc.2008.12.077, 2643875, 19114030.
27. Hartsel S, Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol Sci 1996, 17:445-449. 10.1016/S0165-6147(96)01012-7, 9014498.
28. Oda MN, Hargreaves P, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. Reconstituted high-density lipoprotein enriched with the polyene antibiotic, amphotericin B. J Lipid Res 2006, 47:260-267. 10.1194/jlr.D500033-JLR200, 16314670.
29. Nguyen T-S, Weers PMM, Raussens V, Wang Z, Ren G, Sulchek T, Hoeprich PD, Ryan RO. Amphotericin B induces interdigitation of apolipoprotein stabilized nanodisk bilayers. Biochim Biophys Acta 2008, 1778:303-312. 10.1016/j.bbamem.2007.10.005, 2254181, 17980702.
30. Nelson KG, Bishop J, Ryan RO, Titus R. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice. Antimicrob Agents Chemother 2006, 50:1238-1244. 10.1128/AAC.50.4.1238-1244.2006, 1426947, 16569834.
31. Modolell M, Choi BS, Ryan RO, Hancock M, Titus RG, Abebe T, Hailu A, Müller I, Rogers ME, Bangham CR, Munder M, Kropf P. Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis 2009, 3:e480. 10.1371/journal.pntd.0000480, 2703824, 19597544.
32. Soprano DR, Qin P, Soprano KJ. Retinoic acid receptors and cancers. Annu Rev Nutr 2004, 24:201-221. 10.1146/annurev.nutr.24.012003.132407, 15189119.
33. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001, 1:181-193. 10.1038/35106036, 11902573.
34. Adamson PC. All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia. Oncologist 1996, 1:305-314.
35. Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, Gloghini A, Spina M, Cuneo A, Pomponi F, Bononi A, Doglioni C, Maestro R, Carbone A, Boiocchi M, Dolcetti R. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res 2005, 65:587-95.
36. Kitareewan S, Blumen S, Sekula D, Bissonnette RP, Lamph WW, Cui Q, Gallagher R, Dmitrovsky E. G0S2 is an all-trans-retinoic acid target gene. Int J Oncol 2008, 33:397-404. 2597086, 18636162.
37. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007, 6:793-810. 10.1038/nrd2397, 17906642.
38. Freemantle SJ, Spinella MJ, Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003, 22:7305-7315. 10.1038/sj.onc.1206936, 14576840.
39. Takitani K, Hino N, Terada Y, Kurosawa Y, Koh M, Inoue A, Kawakami C, Kuno T, Tamai H. Plasma all-trans retinoic acid level in neonates of mothers with acute promyelocytic leukemia. Acta Haematol 2005, 114:167-169. 10.1159/000087893, 16227682.
40. Redmond KA, Nguyen T-S, Ryan RO. All-trans retinoic acid nanodisks. Int J Pharm 2007, 339:246-250. 10.1016/j.ijpharm.2007.02.033, 2045639, 17412536.
41. Singh AT, Evens AM, Anderson RJ, Beckstead JA, Sankar N, Sassano A, Bhalla S, Yang S, Platanias LC, Forte TM, Ryan RO, Gordon LI. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol 2010, 150:158-169.
42. Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007, 39:1747-1753. 10.1016/j.biocel.2007.04.026, 17574898.
43. Epstein J, Sanderson IR, Macdonald TTX. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 1994, 26:1-13.
44. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008, 65:1631-1652. 10.1007/s00018-008-7452-4, 18324353.
45. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative Medicine Review 2009, 14:141-153.
46. Ghosh M, Singh ATK, Xu W, Sulchek T, Gordon LI, Ryan RO. Curcumin nanodisks: formulation and characterization. Nanomedicine 2010,
47. De Leon-Rodriguez LM, Lubag AJ, Malloy CR, Martinez GV, Gillies RJ, Sherry AD. Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res 2009, 42:948-957. 10.1021/ar800237f, 2713815, 19265438.
48. Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:169-176. 10.1161/ATVBAHA.108.179275, 19815819.
49. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 2006, 6:2220-2224. 10.1021/nl061498r, 17034087.
50. Cormode DP, Briley-Saebo KC, Mulder WJ, Aguinaldo JG, Barazza A, Ma Y, Fisher EA, Fayad ZA. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4:1437-1444. 10.1002/smll.200701285, 18712752.
51. Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, Calcagno C, Barazza A, Gordon RE, Zanzonico P, Fisher EA, Fayad ZA, Mulder WJ. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett 2008, 8:3715-3723. 10.1021/nl801958b, 2629801, 18939808.
52. Chen W, Vucic E, Leupold E, Mulder WJ, Cormode DP, Briley-Saebo KC, Barazza A, Fisher EA, Dathe M, Fayad ZA. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging 2008, 3:233-242. 10.1002/cmmi.257, 19072768.
53. Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJ, Fayad ZA. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 2010, 24:1689-1699. 10.1096/fj.09-139865, 20075195.
54. Fischer NO, Blanchette CD, Chromy BA, Kuhn EA, Segelke BW, Corzett M, Bench G, Mason PW, Hoeprich PD. Immobilization of his-tagged proteins on nickel-chelating nanolipoprotein particles. Bioconjug Chem 2009, 20:460-465. 10.1021/bc8003155, 19239247.
55. Fischer NO, Infante E, Ishikawa T, Blanchette CD, Bourne N, Hoeprich PD, Mason PW. Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis. Bioconjug Chem 2010, 21:1018-1022. 10.1021/bc100083d, 20509624.
56. Borch J, Torta F, Sligar SG, Roepstorff P. Nanodiscs for immobilization of lipid bilayers and membrane receptors: kinetic analysis of cholera toxin binding to a glycolipid receptor. Anal Chem 2008, 80:6245-6252. 10.1021/ac8000644, 18616345.
57. Matsuo Y, Miura S, Kawamura A, Uehara Y, Rye KA, Saku K. Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis 2007, 194:159-168. 10.1016/j.atherosclerosis.2006.10.020, 17118370.
58. Thaxton CS, Daniel WL, Giljohann DA, Thomas AD, Mirkin CA. Templated spherical high density lipoprotein nanoparticles. J Am Chem Soc 2009, 131:1384-1385. 10.1021/ja808856z, 2843502, 19133723.
59. Peters-Libeu CA, Newhouse Y, Hall SC, Witkowska HE, Weisgraber KH. Apolipoprotein E-dipalmitoylphosphatidylcholine particles are ellipsoidal in solution. J Lipid Res 2007, 48:1035-1044. 10.1194/jlr.M600545-JLR200, 17308333.
60. Wu Z, Gogonea V, Lee X, Wagner MA, Li XM, Huang Y, Undurti A, May RP, Haertlein M, Moulin M, Gutsche I, Zaccai G, Didonato JA, Hazen SL. Double superhelix model of high density lipoprotein. J Biol Chem 2009, 284:36605-36619. 10.1074/jbc.M109.039537, 19812036.
61. Skar-Gislinge N, Simonsen JB, Mortensen K, Feidenhans'l R, Sligar SG, Lindberg B, Bjørnholm T, Arleth L. Elliptical structure of phospholipid bilayer nanodiscs encapsulated by scaffold proteins: casting the roles of the lipids and the protein. J Am Chem Soc 2010, 132:13713-13722. 10.1021/ja1030613, 20828154.